Jazz Pharma Asks Fed. Circ. To Reverse Orange Book Delisting
By Jasmin Boyce · December 19, 2022, 8:23 PM EST
Jazz Pharmaceuticals Inc. has urged the Federal Circuit to undo a federal injunction forcing it to delist a narcolepsy drug-related patent from the U.S. Food and Drug Administration's Orange Book, a database of...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login